In last several years, the focus on the origin and progression of human cancers has shifted from genetic to epigenetic regulation, with particular attention to methylation and acetylation events that have profound effect on the eventual expression of oncogenes and the suppression of tumor suppressors. A few drugs targeting these epigenetic changes have already been approved for treatment, albeit not for lung cancer. With the recent advances in the push towards personalized therapy, questions have been asked about the possible targeting of epigenetic events for personalized lung cancer therapy. Some progress has been made but a lot needs to be done. In this chapter, a succinct review of these topics is provided.
CITATION STYLE
Ahmad, A. (2016). Epigenetics in personalized management of lung cancer. In Advances in Experimental Medicine and Biology (Vol. 890, pp. 111–122). Springer New York LLC. https://doi.org/10.1007/978-3-319-24932-2_6
Mendeley helps you to discover research relevant for your work.